Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial Authors: T A Lalmahomed, E M Monninkhof, M J van Rijssel, H H E van Melick, H M Verkooijen, J C J de Boer, J R N van der Voort van Zyp Published: 2025 ABSTRACT AbstractBackgroundHypofractionation in prostate cancer radiotherapy (RT) has drastically reduced fractionation schemes from 35 to 5 fractions for patients with intermediate-risk prostate cancer, providing good oncological outcomes and well-tolerated treatment toxicity. With an ageing population and a subsequently higher volume of patients with localized prostate cancer, optimizing treatment options is essential to maintain a sustainable healthcare system. Magnetic resonance (MR)-guided RT, allows for the delivery of higher doses of radiation with more accuracy, while limiting genitourinary (GU) and gastrointestinal (GI) toxicity. These advantages facilitate the development of ultrahypofractionation schedules in which the number of treatment fractions can be decreased whilst delivering a sufficient dose for oncological control.The objective of the Two-fraction Ultrahypofractionated Radiotherapy with focal BOost (TURBO) trial is to assess if a radiotherapy schedule of 24 Gy to the prostate in two fractions with a boost to the intraprostatic tumor of up to 27 Gy, is safe and tolerable in terms of treatment toxicity, quality of life, and oncological outcomes.MethodsTURBO is a single-center, open-label, randomized controlled trial, designed to assess non-inferiority over standard treatment. Data are collected within the longitudinal Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM). We will include 160 patients with intermediate risk, localized prostate cancer, who are treated on a 1.5 T MR-linear accelerator (MR-Linac) and randomized (1:1). Participants in the control arm (n = 80) will receive standard of care (36.25 Gy in five fractions, delivered in 16–18 days). Participants in the experimental arm (n = 80) are treated with two fractions of 12 Gy to the prostate, with a boost of up to 13.5 Gy to the gross tumor volume (GTV) in 8 days. The main endpoint is Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 GU acute toxicity (up to 90 days after treatment). Secondary outcomes are acute GI toxicity and late GU and GI toxicity 1, 2, and 5 years after treatment, as well as QoL through assessment of patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-PR15, EQ-5D-5L) and biochemical recurrence and overall survival up to 5 years.DiscussionTURBO compares a 2-fraction radiotherapy course of 12 Gy per fraction to the clinical target volume (CTV) with a simultaneously integrated boost to the GTV of up to 13.5 Gy to a standard 5-fraction course of 7.25 Gy per fraction. The objective is to assess non-inferiority in terms of treatment toxicity and to compare oncological outcomes.Trial registrationClinicalTrials.gov Identifier NCT06518226. Registered on 24 July 2024. First participant included on March 28th 2024.Keywords: MR-guided adaptive radiotherapy, Quality of life, Patient-reported outcomes, Prostate cancer, Ultrahypofractionation Administrative information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). Title {1}Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trialTrial registration {2a and 2b}.ClinicalTrials.gov IdentifierNCT06518226. Retrospectively registered on 24 July 2024Protocol version {3}19-01-2024, version 3.1Funding {4}Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsAuthor details {5a}T.A. Lalmahomed, MD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsE.M. Monninkhof, PhD, Julius Center for Primary Care and Health Sciences, University Medical Center Utrecht, Utrecht University, Utrecht, the NetherlandsM.J. van Rijssel, PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsH.H.E. van Melick, MD PhD, Department of Urology, Sint Antonius Ziekenhuis, Utrecht-Nieuwegein, the NetherlandsH.M. Verkooijen, MD PhD, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands & Imaging Division, Netherlands Cancer Institute, Amsterdam, the NetherlandsJ.C.J de Boer, PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsJ.R.N. van der Voort van Zyp, MD PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsName and contact information for the trial sponsor {5b}University Medical Center Utrecht (UMC Utrecht), Heidelberglaan 100, 3584CX Utrecht, the NetherlandsRole of sponsor {5c}The study sponsor is not involved in the study design; collection, management, analysis, and interpretation of data; writing of the report; or the decision to submit the report for publication. T.A. Lalmahomed, MD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands E.M. Monninkhof, PhD, Julius Center for Primary Care and Health Sciences, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands M.J. van Rijssel, PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands H.H.E. van Melick, MD PhD, Department of Urology, Sint Antonius Ziekenhuis, Utrecht-Nieuwegein, the Netherlands H.M. Verkooijen, MD PhD, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands & Imaging Division, Netherlands Cancer Institute, Amsterdam, the Netherlands J.C.J de Boer, PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands J.R.N. van der Voort van Zyp, MD PhD, Department of Radiation Oncology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands Introduction Background and rationale {6a} Prostate cancer is the most common non-cutaneous cancer in men, with an incidence of 15,000 cases in 2024 in The Netherlands [1]. Worldwide, there were 1.4 million diagnoses in 2020 and in Europe it is the third cancer-related cause of death in men [2, 3]. In The Netherlands, 60% of men diagnosed with prostate cancer present with limited localized disease. Of these, about two-thirds have low or intermediate risk disease, which is likely to be cured with radical treatment such as radiotherapy (RT) or (robot-assisted) prostatectomy [4]. Patients with low risk disease often undergo active surveillance, and approximately 10% of patients on active surveillance opt for active treatment for reasons such as patient anxiety [5]. Half of patients with localized low or intermediate risk disease who are actively treated, opt for radiotherapy [5, 6]. The feasibility and safety of hypofractionated stereotactic body radiotherapy (SBRT) for intermediate risk prostate cancer has been extensively studied. A large meta-analysis on SBRT for intermediate risk prostate cancer patients reported a 5-year biochemical recurrence-free survival of 92% and GU and GI grade 3 or more toxicity in less than 1% of patients [7]. Over the past years, radiotherapy fractionation schemes have been reduced as hypofractionated radiotherapy regimens have emerged. Further advances have led to a reduction from 35 (total dose 77 Gy) to 20 fractions (total dose 62 Gy), and since recently the standard of care for intermediate risk disease is hypofractionation in 5 fractions (total dose of 36.25 Gy) delivered over the course of 16–18 days [8–11]. With the incidence of localized prostate cancer continuing to rise and associated treatment costs increasing, there is a need to further enhance and optimize current treatment options [12]. An early economic health evaluation showed that a 2-fractionation scheme with MRI-guided radiotherapy (MR-guided RT) for intermediate-risk prostate cancer patients might be cost effective compared to the standard of care 5-fraction scheme [13]. Previous studies demonstrated the feasibility of delivering high doses of radiation in only two fractions, both in silico as well as in a clinical setting using a conventional CT-guided linear accelerator [14–16]. With the introduction of online adaptive MR-guided RT, it has become possible to precisely delineate soft tissue targets such as the prostate and the intraprostatic tumor and surrounding organs at risk during each fraction. In clinical practice, this allows for the delivery of higher doses of radiation to targets with more accuracy, while limiting organs at risk exposure and thus minimizing genitourinary (GU) and gastrointestinal (GI) toxicity. In the phase III, randomized controlled FLAME trial, 35 fractions of 2.2 Gy in a computed tomography (CT)-guided RT setting for NCCN-criteria intermediate and high-risk localized prostate cancer with and without a simultaneously integrated focal boost of up to 2.7 Gy per fraction, were compared. Biochemical disease-free survival (bDFS) was significantly higher in the group that received the boost. Furthermore, both physician-reported GU and GI, as well as patient-reported toxicity were comparable in both groups [9]. This trend is also seen in the results of the following hypo-FLAME and hypo-FLAME 2.0 trials, studying the effect of a focal boost in hypofractionation schedules [17–19]. By combining a two-fraction radiotherapy schedule with a simultaneously integrated boost to the intraprostatic tumor, with a biologically equivalent dose to previously proven safe doses in a MR-guided SBRT setting (EQD2 = 84 Gy, assuming α/β of 2), we aim to demonstrate non-inferiority in terms of toxicity to the standard treatment of intermediate-risk prostate cancer radiotherapy. Secondarily, oncological control will be assessed. Objectives {7} The primary objective of this study is to compare grade ≥ 2 genitourinary (GU) acute (within 90 days of treatment) toxicity of ultrahypofractionated adaptive MR-guided RT in two fractions with an isotoxically planned focal boost compared to five fractions without a boost. Toxicity will be measured through scoring of Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by the physician [20]. Secondary objectives to be compared between study arms are: Acute gastrointestinal (GI) CTCAE grade ≥ 2 toxicity Acute gastrointestinal (GI) CTCAE grade ≥ 2 toxicity Late CTCAE GU and GI toxicity at timepoints 1, 2, and 5 years after the end of treatment Late CTCAE GU and GI toxicity at timepoints 1, 2, and 5 years after the end of treatment Patient-reported quality of life, using the following validated patient-reported outcome measures (PROMs):oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-C30.oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-PR25oEuroQol–5 dimensions–5 levels (EQ-5D-5L) Patient-reported quality of life, using the following validated patient-reported outcome measures (PROMs):oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-C30.oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-PR25oEuroQol–5 dimensions–5 levels (EQ-5D-5L) oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-C30. European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-C30. oEuropean Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-PR25 European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire(QLQ)-PR25 oEuroQol–5 dimensions–5 levels (EQ-5D-5L) EuroQol–5 dimensions–5 levels (EQ-5D-5L) Overall survival up to 5 years Overall survival up to 5 years Biochemical progression free survival and time to relapse up to five years, through evaluation of prostate-specific antigen (PSA). Biochemical progression free survival and time to relapse up to five years, through evaluation of prostate-specific antigen (PSA). Trial design {8} TURBO is a single-center, open label, phase 2, non-inferiority randomized controlled trial. Participants are randomized in a 1:1 ratio between the intervention and the control group. Sequence generation for randomization is determined by permutated blocks of sizes 2, 4, and 6 through the web-based program Castor Electronic Data Capture (Amsterdam, The Netherlands). The study environment in this program is managed by an independent data manager. Methods: participants, interventions, and outcomes Study setting {9} Participants will be patients with intermediate risk, localized prostate cancer who have opted for radiotherapeutic treatment at the Department of Radiotherapy of University Medical Center (UMC) Utrecht. Data collection is facilitated by the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-linac (MOMENTUM) study (NCT04075305). Eligibility criteria {10} Patients must meet the following inclusion criteria to be eligible for this trial: At least 18 years of age At least 18 years of age Primary prostate cancer Primary prostate cancer Histopathological confirmation of prostate adenocarcinoma Histopathological confirmation of prostate adenocarcinoma Multidisciplinary team indication for radical treatment Multidisciplinary team indication for radical treatment Choice of treatment is radical radiotherapy Choice of treatment is radical radiotherapy Intermediate risk prostate cancer, according to the European Association of Urology (EAU) risk classification:oPSA 10–20 ng/ml ORoGleason score = 7 (ISUP grade group 2 or 3) ORoClinical T (cT)-stadium 2b based on digital rectal examination Intermediate risk prostate cancer, according to the European Association of Urology (EAU) risk classification:oPSA 10–20 ng/ml ORoGleason score = 7 (ISUP grade group 2 or 3) ORoClinical T (cT)-stadium 2b based on digital rectal examination oPSA 10–20 ng/ml OR PSA 10–20 ng/ml OR oGleason score = 7 (ISUP grade group 2 or 3) OR Gleason score = 7 (ISUP grade group 2 or 3) OR oClinical T (cT)-stadium 2b based on digital rectal examination Clinical T (cT)-stadium 2b based on digital rectal examination Imaging T-stadium ≤ 3a, non-bulky (largest diameter of the intraprostatic dominant lesion < 20 mm in the axial plane on mpMRI (diffusion-weighted imagin for peripheral zone, T2-sequence for transition zone)) Imaging T-stadium ≤ 3a, non-bulky (largest diameter of the intraprostatic dominant lesion < 20 mm in the axial plane on mpMRI (diffusion-weighted imagin for peripheral zone, T2-sequence for transition zone)) Have given written informed consent for inclusion in the MOMENTUM study and to fill out QLQs in the MOMENTUM study. Have given written informed consent for inclusion in the MOMENTUM study and to fill out QLQs in the MOMENTUM study. The following are exclusion criteria for eligibility for this trial: Contraindications for MR-imaging Contraindications for MR-imaging International Prostate Symptom Score (IPSS) ≥ 15 International Prostate Symptom Score (IPSS) ≥ 15 Prostate volume > 80 ml Prostate volume > 80 ml Comorbidities predisposing to significant radiotherapy treatment-related toxicity, e.g. inflammatory bowel disease Comorbidities predisposing to significant radiotherapy treatment-related toxicity, e.g. inflammatory bowel disease Metal pelvic implants causing artefact on MR-imaging sequences Metal pelvic implants causing artefact on MR-imaging sequences Previous pelvic radiotherapy Previous pelvic radiotherapy Diagnosed with an invasive malignancy within the 5 last years, exclusion basal cell carcinoma of the skin. Diagnosed with an invasive malignancy within the 5 last years, exclusion basal cell carcinoma of the skin. Who will take informed consent? {26a} Informed consent will be obtained by the coordinating researcher of the trial. Attending radiation oncologists will identify eligible patients based on the prespecified inclusion and exclusion criteria and will provide the patient with written study information. After a patient has had time to reflect on the study, a researcher will contact them. The researcher will answer any remaining questions and schedule a consultation to obtain written informed consent. Once consent is provided, the patient will be randomized, and the randomization result will be communicated immediately. Additional consent provisions for collection and use of participant data and biological specimens {26b} Not applicable, no additional samples will be collected. Interventions Explanation for the choice of comparators {6b} The control group in this trial is prescribed the standard of care radiotherapy schedule for intermediate risk prostate cancer at the UMC Utrecht. Participants in this group will receive 5 fractions of 7.25 Gy to the clinical target volume (CTV) consisting of the prostate, the base of the seminal vesicles (5 mm) and the gross tumor volume (GTV) that will receive an additional margin of 4 mm. A 2 mm isotropic CTV-to-PTV margin with prostate gating will be used. The treatment dose is planned to be delivered homogeneously with maximum hotspots of ≤ 107% within the PTV. The treatment is delivered over a period of 16–18 days on a 1.5 T MR-Linac. Intervention description {11a} The intervention group in this trial receives 2 fractions of radiotherapy treatment with a homogeneously planned dose of 12 Gy to the CTV, with a simultaneously integrated isotoxic boost of 13.5 Gy to the GTV, delivered in 8 days on a 1.5 T MR-Linac. Coverage goals for target volumes are as follows: GTV: D95% > 27 Gy, D0.1 cc < 34 Gy GTV: D95% > 27 Gy, D0.1 cc < 34 Gy CTV: D99% > 22.8 Gy CTV: D99% > 22.8 Gy PTV: D97% > 22.8 Gy, limiting spots outside of PTV > 25.7 Gy. PTV: D97% > 22.8 Gy, limiting spots outside of PTV > 25.7 Gy. Dose constraints are presented in Table 1. Table 1Dose constraints for organs at risk in both treatment groups5 × 7.25 Gy (control)2 × 12 Gy (experimental)RectumD0.5 cc≤ 40 GyNAD1cc≤ 38 Gy< 22 GyD4ccNA< 17.6 GyD7ccNA< 13 Gy (soft constraint)V28Gy≤ 15%/20%NAV32Gy≤ 10%/15%NASphincterDmean< 20 Gy< 13 GySmall bowelD0.5 cc< 32 GyV12 < 5 ccD10cc< 25 GyNABladderD0.5 cc< 42 Gy< 25.5 GyD5cc< 37 Gy< 22 GyV28Gy< 15%/20%NAV32Gy< 10%/15%NAUrethraD0.5 cc< 42 Gy< 27 GyFemoral headD10cc< 30 Gy< 14 GyPenile bulbV19 Gy< 50% Dose constraints for organs at risk in both treatment groups As is the case in the control group, a daily MR image is acquired and contours and dose distribution are fully adapted to the daily anatomy for each fraction. Continuous MR imaging and, when necessary, plan adaptation during dose delivery are employed to correct for significant intra-fraction motion using Comprehensive Motion Management software (Elekta AB, Stockholm), allowing for 2 mm isotropic CTV-to-PTV margins to be used. The radiation oncologist will consult with the participant directly after the second treatment fraction to score treatment toxicity. Further follow-up is according to protocol at our center. Criteria for discontinuing or modifying allocated interventions {11b} Only participants who meet the eligibility criteria will be randomized. The experimental treatment or standard treatment can be discontinued or modified for urgent medical reasons. Patients can withdraw consent for the intervention and/or participation in the MOMENTUM study (also withdrawing from the TURBO trial due to the shared study infrastructure), or solely from the TURBO trial at any time, for any reason and without any consequences. If a participant withdraws after receiving the first fraction of the experimental intervention, the patient will receive three additional fractions of 7 Gy to the prostate (± seminal vesicles, based on initial delineation). This will match the biologically equivalent dose (EQD2) delivered in the standard treatment schedule of 36.25 Gy. Strategies to improve adherence to interventions {11c} Patients receive extensive study guidance and counselling. This includes written patient information as well as an in-person consultation with a researcher. The importance of completing the prescribed radiotherapy schedule is also emphasized. As the intervention consists of two radiotherapy fractions, no strategies are in place to improve adherence to the intervention after the start of radiotherapy. Relevant concomitant care permitted or prohibited during the trial {11d} No concomitant care, interventions and medications will be prohibited during the trial. Provisions for post-trial care {30} A comparable feasibility study demonstrated physician-reported acute grade 2 GU toxicity in 10% in the 5-fraction group, and in 20% in the 2-fraction group 12 weeks after radiotherapy treatment [16]. In the literature, acute GU toxicity after a 5-fraction RT schedule is approximately 20% [21–23]. Therefore, no specific provisions for post-trial care are incorporated. Treatment-related toxicity will be evaluated at standard follow-up visits. Outcomes {12} The main endpoint of this study is the difference in proportion of patients with CTCAE GU grade ≥ 2 physician-reported toxicity 90 days after treatment (acute toxicity), between the intervention group and the control group. CTCAE events will be scored according to the CTCAE version 5 dictionary, available from https://safetyprofiler-ctep.nci.nih.gov/safety-profiler/index.html. This outcome measure is chosen as it reflects clinically relevant toxicity, for which a medical intervention, e.g. prescription of medication, is required. The use of alpha blockers in any circumstance will be qualified as grade 2 toxicity. Secondary outcomes that will be compared across study arms are: CTCAE late GU and acute and late gastrointestinal (GI), physician reported toxicity 1, 2, and 5 years after treatment CTCAE late GU and acute and late gastrointestinal (GI), physician reported toxicity 1, 2, and 5 years after treatment Patient-reported quality of life (QoL) at 3 months, and 1, 2, and 5 years after treatment. The following questionnaires will be used to measure QoL:oEORTC-QLQ-C30 to assess QoL related to oncological treatment, non-specific to tumor site [24]. It consists of a functional domain for which a higher score corresponds to a higher level of functioning, and a symptom domain for which a higher score corresponds to having more symptoms.oEORTC-QLQ-PR25 to assess QoL related to prostate cancer treatment [25]. This also consists of a functional domain and a symptom domain.oEQ-5D-5L questionnaire to assess general QoL and to establish cost-effectiveness [26]. Findings can be used for health-technology assessment. Patient-reported quality of life (QoL) at 3 months, and 1, 2, and 5 years after treatment. The following questionnaires will be used to measure QoL:oEORTC-QLQ-C30 to assess QoL related to oncological treatment, non-specific to tumor site [24]. It consists of a functional domain for which a higher score corresponds to a higher level of functioning, and a symptom domain for which a higher score corresponds to having more symptoms.oEORTC-QLQ-PR25 to assess QoL related to prostate cancer treatment [25]. This also consists of a functional domain and a symptom domain.oEQ-5D-5L questionnaire to assess general QoL and to establish cost-effectiveness [26]. Findings can be used for health-technology assessment. oEORTC-QLQ-C30 to assess QoL related to oncological treatment, non-specific to tumor site [24]. It consists of a functional domain for which a higher score corresponds to a higher level of functioning, and a symptom domain for which a higher score corresponds to having more symptoms. EORTC-QLQ-C30 to assess QoL related to oncological treatment, non-specific to tumor site [24]. It consists of a functional domain for which a higher score corresponds to a higher level of functioning, and a symptom domain for which a higher score corresponds to having more symptoms. oEORTC-QLQ-PR25 to assess QoL related to prostate cancer treatment [25]. This also consists of a functional domain and a symptom domain. EORTC-QLQ-PR25 to assess QoL related to prostate cancer treatment [25]. This also consists of a functional domain and a symptom domain. oEQ-5D-5L questionnaire to assess general QoL and to establish cost-effectiveness [26]. Findings can be used for health-technology assessment. EQ-5D-5L questionnaire to assess general QoL and to establish cost-effectiveness [26]. Findings can be used for health-technology assessment. Overall survival (OS) up to 5 years Overall survival (OS) up to 5 years Biochemical progression free survival (bPFS), disease-free survival (DFS) after 1, 2, and 5 years, through assessment of PSA levels. Biochemical recurrence is defined as an increase of the PSA level of at least 2 ng/ml compared to the nadir PSA level after radical treatment. Biochemical progression free survival (bPFS), disease-free survival (DFS) after 1, 2, and 5 years, through assessment of PSA levels. Biochemical recurrence is defined as an increase of the PSA level of at least 2 ng/ml compared to the nadir PSA level after radical treatment. Participant timeline {13} The participant timeline is visualized in Table 2. Table 2Participant timelineAfter intake with radiation oncologist, before treatmentAfter informed consent procedureTreatmentPost-allocationTimepointPre-RT (baseline)Radiotherapy3 months6 months1 year2 years5 yearsEnrolment: Informed consent MOMENTUM studyX Eligibility screening TURBO studyX Informed consent TURBO studyX Randomization TURBO studyXInterventions: TURBO interventionX Standard of careX[List other study groups]Assessments: CTCAE toxicity scoringXXXXXX PROMs collectionXXXXXX PSA retrievalXXXXXX Participant timeline Sample size {14} The sample size calculation is based on the rate of CTCAE grade ≥ 2 GU toxicity in the control group to be 18–23%, as has been shown in previous studies researching 5-fractions of MR-guided RT in localized prostate cancer treatment [21, 22] 146 participants would be required to be 80% sure that the upper limit of a one-sided 95% confidence interval (CI) will exclude a difference in favor of the standard group of more than 20%. This non-inferiority margin is set at 20%, as a doubling of CTCAE grade ≥ 2 GU toxicity in the intervention group compared to the control group is clinically unacceptable. Following this reasoning, 73 participants would be needed per group. To correct for an anticipated 10% participant drop out, 160 participants will be accrued in total. Recruitment {15} Patients with an appointment at the Department of Radiation Oncology of UMC Utrecht will be screened for eligibility by treating physicians as well as a researcher. No additional, external recruitment strategies will be deployed. Assignment of interventions: allocation Sequence generation {16a} Allocation of intervention will be done through permuted block randomization, with block sizes of 2, 4 and 6. Participants will be randomized into the intervention or control groups at a 1:1 ratio. Randomization will not be stratified. Concealment mechanism {16b} Randomization is done using the built-in functions of Castor Electronic Data Capture (Amsterdam, the Netherlands, www.castoredc.com). This web-based electronic data capture service discloses the randomization result only after a participant has been recruited and registered as such. Implementation {16c} Participants who have given informed consent for inclusion in the trial are enrolled by members of the study team. Subsequently, they are registered as participants in the described web-based data capture service which is used to assign them to an intervention. Assignment of interventions: blinding Who will be blinded {17a} This is an open-label trial. Participants, attending physicians and researchers will be aware of the received treatment. Given the objectively measurable endpoints of this study, this is expected not to introduce substantial bias. Procedure for unblinding if needed {17b} Not applicable, this is an open-label trial. Data collection and management Plans for assessment and collection of outcomes {18a} MOMENTUM is an international cohort study in which patient and treatment characteristics, as well as clinical outcomes and PROs are collected to evaluate the 1.5 T Unity MR-Linac [27, 28]. For TURBO, data collected within MOMENTUM will be used. Eligible patients will be required to consent to inclusion in both studies and explicitly to receive QLQs in MOMENTUM. Data from the following time points in the MOMENTUM study will be used for effect estimation in the TURBO trial: baseline (pre-RT), three months post-RT, and 1, 2, and 5 years post-RT. Demographic and clinical data (including CTCAE scores and PSA) are extracted from participants’ electronic patient record files in the hospital information system. The PROMs (EORTC-QLQ-C30, EORTC-QLQ-PR25 and the EQ-5D-5L) are sent electronically using Castor Electronic Data Capture (Amsterdam, The Netherlands). Plans to promote participant retention and complete follow-up {18b} The primary endpoint will be scored by treating physicians during a routine consultation three months post-RT. If a follow-up consultation at three months is not planned, a member of the study team will reach out by phone to assess the primary endpoint. At each follow-up consultation, the CTCAE score will be recorded. To this end, no participant retention strategy is necessary. Participants who do not fill out a questionnaire within a week of receiving it, receive an automated reminder per email. Data management {19} Data are captured in the electronic data capture system Castor (Amsterdam, The Netherlands, www.castoredc.com). This database is managed by data managers from the MOMENTUM study team, and includes multiple built-in skips and validation checks, as well as an electronic audit trail log for transparency purposes and to adhere to the principles of Good Clinical Practice. PROMs are sent through Castor, using built-in functionalities of the program. Questionnaires are completed online. Other study files are stored in a digital local secured research folder, or in a secured offline location at the UMC Utrecht premises. Confidentiality {27} Data will be handled in compliance with the European General Data Protection Regulation (GDPR). Study participants are assigned a subject identification number, which will be used to code any data related to this participant. The subject identification number code list will be accessible by members of the MOMENTUM and TURBO study teams. Informed consent forms are stored in secure study site archives. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} Not applicable. No biological specimens will be collected or stored for this study. Statistical methods Statistical methods for primary and secondary outcomes {20a} The primary study parameter is the difference (± 90% CI) in the cumulative rate of GU toxicity grade ≥ 2 in the interventional and control arm, occurring in the timeframe between the start of treatment and 12 weeks after the last fraction. For the primary study parameter, if the upper limit of the one-sided 95% CI for the difference in cumulative GU toxicity (control − intervention) is less than 20 percentage points, then the interventional arm is considered non-inferior. CIs are calculated with a critical value (z-score) of 1.65 and conform to standard calculations. After consideration, no correction for prognostic factors or confounders will be made. Due to the randomized nature of this study, the assumption is that confounding and prognostic factors will be evenly distributed between both groups. Physician-reported toxicities listed as secondary endpoints will be analyzed by indexing the highest grade of reported toxicity in these domains to have occurred at the prespecified follow-up moment (i.e., baseline, after treatment, 4 and 12 weeks, 1-, 2-, and 5-year post-treatment). Repeated measures analysis by a generalized estimating equation with adjustment for baseline will be performed to test for statistical significance between the study groups overall and at different time points. Patient-reported quality of life will be analyzed using repeated measures analysis (mixed models). Independent factors will be time, group, time*group and baseline value of the outcome. Clinical relevance of these patient-reported outcomes will be assessed by comparing findings with minimally clinically important differences (MCIDs). Time to event endpoints (PSA control, bDFS, DFS, OS) will be presented graphically using Kaplan-Meier plots and summarized using Kaplan-Meier estimates of event rates at 2 and 5 years (with 90% CI). Should reason exist to perform a multivariate analysis to account for predictors, appropriate methods such as a Cox proportional hazards model, will be used. Interim analyses {21b} No interim analyses are planned. Methods for additional analyses (e.g., subgroup analyses) {20b} No additional analyses are planned. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} Data will be analyzed on an intention-to-treat principle. We assume that patients will be willing to accept the experimental treatment. No measures to account for non-adherence or missing data are included in the study protocol. Plans to give access to the full protocol, participant-level data and statistical code {31c} After publication of the main results of the study, anonymized study data can be made accessible upon reasonable request. When data are requested through the MOMENTUM Consortium that include data of TURBO participants, disclosure of the data is up to the discretion of the Principal Investigator (PI). Oversight and monitoring Composition of the coordinating center and trial steering committee {5d} This single-center study is coordinated from UMC Utrecht. The principal investigator and coordinating investigators are responsible for monitoring the study progress. The PI and coordinating investigator meet weekly to discuss trial conduct. Radiation oncologists treating trial participants are briefed on trial logistics monthly. Investigators, medical physicists and radiation therapy technologists discuss operational matters regarding the trial at a biweekly meeting. Composition of the data monitoring committee, its role and reporting structure {21a} No data monitoring committee is installed, as the institutional review board considers the risk imposed in this study to be negligible. Adverse event reporting and harms {22} All adverse events reported spontaneously by the subject or observed by the investigator, or their staff will be recorded. The sponsor will report the serious AEs (SAEs), that occur between the date of inclusion up to and including 6 months after the study-related intervention to the Institutional Review Board (IRB) within 7 days if they are life-threatening or result in death. Other SAEs will be reported to the IRB within 15 days of notice. All AEs will be followed until they have abated, or until a stable situation has been reached. A yearly progress report of the study, including information on AEs and SAEs will be shared with the IRB. To ensure the safety of the intervention, stopping rules have been formulated. These are based on incidence rates of grade 3 acute GU-toxicity in a 5-fraction MR-guided RT setting between 0 and 0.6% and those of GI-toxicity to be 0% [21, 22]. The study will be terminated if: Twelve weeks after the 10th participant of the intervention group has completed treatment, the incidence of grade 3 GU-toxicity is or exceeds 30% or higher (3 or more participants) Twelve weeks after the 10th participant of the intervention group has completed treatment, the incidence of grade 3 GU-toxicity is or exceeds 30% or higher (3 or more participants) Twelve weeks after the 50th participant of the intervention group has completed treatment, the incidence of grade 3 GU-toxicity is 10% (5 or more participants). Twelve weeks after the 50th participant of the intervention group has completed treatment, the incidence of grade 3 GU-toxicity is 10% (5 or more participants). Frequency and plans for auditing trial conduct {23} An independent data monitor is appointed to monitor study progression, the presence of essential documents such as informed consent forms, adherence to the study protocol and standard operating procedures (SOPs), as required by the Dutch Medical Research Involving Human Subjects Act (WMO). Furthermore, they will assess data for completeness and verify its accuracy (source data verification). Issues will be communicated to the PI. The monitor is involved until the close-out visit of the study, after full completion. The monitor will audit the study at the following instances: once before the start of the study, after the inclusion of the first 10 participants, and once every two years thereafter. After completing the follow-up of the last participant, the monitor will perform a close-out visit. Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25} Amendments to the study protocol that affect the safety or rights of participants, the robustness of generated data or the conduct of the study will be presented to the IRB and will have to be approved before they can be implemented. After approval, changes are communicated with those involved in the study. If changes affect participants, they will be provided with the necessary information. Any deviations from the study protocol will be recorded in the Investigator Site File. Any changes to the initial protocol will be updated on relevant trial registries. Dissemination plans {31a} Trial results will be shared with peers through presentations at scientific meetings, and through the publication of peer-reviewed scientific articles. Patient and public involvement While designing this trial, the Prostaatkankerstichting (Dutch prostate cancer federation) was contacted to assess if the study was deemed of interest for the broader patient population. Their positive recommendation was received and presented to the IRB at the time of trial registration. Discussion This trial builds on the HERMES trial (NCT04595019) which has completed accrual and of which the first results have been published [16]. TURBO, however, is powered to demonstrate non-inferiority regarding physician-reported toxicity over a standard radiotherapy schedule of five fractions. As a tertiary radiotherapy referral center, the UMC Utrecht has extensive experience with prostate cancer radiotherapy, and MR-guided RT in particular. The FLAME trial yielded evidence of the benefit on oncological outcomes of the implementation of a simultaneously integrated boost for the treatment of localized prostate cancer in a conventionally fractionated radiotherapy schedule [9]. Studies investigating the benefit of such a boost in a hypofractionation setting are ongoing [17, 18]. However, this is one of the pioneering studies to deploy this technique in a two-fraction radiotherapy schedule. The prescribed doses of 12 Gy per fraction to the CTV (24 Gy in total) and a boost of up to 13.5 Gy per fraction to the intraprostatic tumor or the GTV (27 Gy in total) correspond to doses delivered in currently used radiotherapy schemes after conversion using the linear quadratic model [29, 30]. Trial patients will be followed up clinically for 5 years by their attending radiation oncologist and medical data will be collected from patients’ medical files as per their informed consent for the MOMENTUM study. Through this infrastructure of clinical follow-up and data collection in a research setting, the additional burden on patients enrolled in this trial is minimal. The duration of the clinical follow-up, combined with the center’s experience in MR-guided RT and innovations within the field and inclusion in a prospective registry, makes for a highly monitored and safe setting for this trial to be conducted. With this trial, we aspire to make a societal and scientific impact, paving the way for broad implementation of a shorter and intensified treatment schedule to maintain a vital healthcare system with attention to patient needs and experiences. Trial status Study protocol version 3.1 was approved by the IRB NedMec, Utrecht, The Netherlands, on 19 January 2024. Recruitment began in March 2024 and is expected to end in 2027. Acknowledgements Not applicable. Abbreviations Adverse event (Biochemical) disease-free survival Confidence interval Computed tomography Common Terminology Criteria of Adverse Events Clinical target volume Disease-free survival European Association of Urology External beam radiation therapy European Organization for Research and Treatment of Cancer General Data Protection Regulation; in Dutch: Algemene Verordening Gegevensbescherming (AVG) Gastrointestinal Gross tumor volume Genitourinary Gray International Prostate Symptom Score Institutional Review Board Minimally clinically important differences The “Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac” study Magnetic resonance-guided radiotherapy 7MV Elekta accelerator mounted on a ring around a modified 1.5 T Philips Ingenia MRI system Overall survival Principal investigator Patient-reported outcome (measure) Prostate-specific antigen Quality Of Life Questionnaire Quality Of Life Radiotherapy Serious adverse event Stereotactic body radiation therapy Standard operating procedure University Medical Center Medical Research Involving Human Subjects Act; in Dutch: Wet Medisch-wetenschappelijk Onderzoek met Mensen Authors’ contributions {31b} JV and JB conceived and designed the study. TL, EM, MR, JB, and JV wrote the study protocol. JV and TL are responsible for the supervision of the trial. TL drafted the manuscript, which was reviewed substantively by HM, HV, and JV. All authors read, provided feedback, and approved the final manuscript. Funding {4} Operational costs for this trial are carried by the Department of Radiation Oncology of UMC Utrecht. There was no additional funding. The funder is not involved in study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication. Data availability {29} The final trial dataset will be available to the researchers involved and will be freely available without limitation by contractual or other legal agreements. Upon publication of the study results, study data can be requested from the PI or the corresponding investigator of the study. Declarations Ethics approval and consent to participate {24} This study is approved by the medical ethical review board NedMec, Utrecht, The Netherlands, on 19 January 2024 (reference number 23–249). Patients are asked for informed consent to participate in the study, knowing that they will be randomized between the standard and the experimental arm; for the use of data collected within this study for future research, and to be approached by the study team for future studies. Consent for publication {32} Participant information materials and the informed consent form are available from the corresponding author upon request. Competing interests {28} HM Verkooijen receives research funding from Elekta, the European Commission, the Dutch Cancer Foundation and the Dutch Research Council. JRN van der Voort van Zyp receives speaker fees from Elekta and Prevents. The other authors do not have any competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information T. A. Lalmahomed, Email: t.a.lalmahomed-2@umcutrecht.nl J. R. N. van der Voort van Zyp, Email: j.r.n.vandervoortvanzyp@umcutrecht.nl References Associated Data Data Availability Statement The final trial dataset will be available to the researchers involved and will be freely available without limitation by contractual or other legal agreements. Upon publication of the study results, study data can be requested from the PI or the corresponding investigator of the study.